期刊论文

Relationship between visfatin and new-onset atrial fibrillation after PPCI in patients with ST elevation myocardial infarction

中文

中国动脉硬化杂志

1007-3949

2018

26

7

678-684

10.3969/j.issn.1007-3949.2018.07.006

81470435:国家自然科学基金 81700306:国家自然科学基金 2017M622588:中国博士后科学基金

本校为第一机构

目的 循环内脂素(visfatin)水平高低与急性ST段抬高型心肌梗死(STEMI)患者的全因死亡发生具有相关性.据此推测,较高的内脂素可能与主要不良心血管事件(MACE)的发生有关,并增加急诊经皮冠状动脉介入治疗(PPCI) STEMI患者心房颤动(AF)的发生率.方法 604例接受PPCI治疗的STEMI患者纳入研究.使用ELISA法测量术前血浆内脂素浓度.随访1年,记录术后AF及MACE发生率,并分析血浆内脂素水平与MACE、新发AF之间的关系.结果 在604例患者中,新发AF42例(6.95％).与术后无AF患者相比,新发AF患者1年MACE发生率升高(45.24％比19.57％,P＜0.05).此外,与血浆低水平内脂素(≤14.5 μg/L)患者相比,血浆高水平内脂素(＞...

Aim Circulating visfatin levels has reflected the long-term survival in patients with ST-elevation myocardial infarction（ STEMI）. It postulated that higher visfatin would be linked to increased risk for atrial fibrillation（ AF）and major adverse cardiovascular events（ MACE） in patients with STEMI treated with primary percutaneous coronary intervention（ PPCI）. Methods 604 patients with acute STEMI underwent the PPCI were enrolled in the study. ELISA was used to measure plasma visfatin concentrations. One-year MACE and adverse events were ...